Psychiatry (PGY-4 and Above)
www.traini...@nih.gov
Donald Rosenstein, MD
<H3>Overview</H3>
<P>The Clinical Associates Program
of the National Institute of Mental Health
(see http://www.nimh.nih.gov ) Intramural Research Program offers extensive training opportunities in
clinical and basic psychiatric research and is accredited by the Accreditation
Council in Graduate Medical Education to provide training for residents in the
PGY-4 and above. The core two year training program focuses on the acquisition
and refinement of research skills, including the evaluation and clinical care
of research subjects, development of research protocols, performance of clinical
and/or laboratory research, and preparation and presentation of study results.
Associates join specialty branches or sections that study the mechanisms or treatments
of major psychiatric illnesses. Emphasis in these programs is on psychopharmacology,
neuroendocrinology, circadian physiology, brain imaging, molecular biology, and
neurogenetics.</P>
<H3>Structure of the Clinical Training Program</H3>
<P>Clinical and research training are integrated during the two-year Clinical
Associates Program. Fellows assume responsibility for the evaluation and clinical
care of inpatient and/or outpatient research subjects, in addition to providing
psychiatric consultation to NIH patients. The trainee is encouraged to develop
areas of research that may be translated into clinical protocols. Research design,
methodology, statistical analysis and data presentation skills are developed through
interaction with mentors, didactic sessions, and practical experiences. For trainees
with primarily laboratory interests, basic research training opportunities are
available.</P>
<H3>Program Faculty and Research Interests</H3>
<H4>Biological Psychiatry Branch</H4>
<UL>
<LI>Robert M. Post, MD. Course and treatment of bipolar affective illness; mechanism
of action of lithium and the anticonvulsants carbamazepine and valproate; amygdala
kindling; and mechanisms underlying cocaine-induced behavioral sensitization.
</LI>
<LI>Una McCann, MD. Phenomenology, neuroendocrinology, and treatment of anxiety
disorders (especially panic disorder and social phobia), including phenomenology
and neuropharmacology of sleep panic attacks, and chemical models of anxiety.
</LI>
<LI>David R. Rubinow, MD. Basic mechanisms and clinical manifestations of endocrine
and immune effects on mood, cognition, and behavior; biological characterization
and treatment of reproductive endocrine- related mood disorders.
</LI>
</UL>
<H4>Clinical Neuroendocrinology Branch</H4>
<UL>
<LI>Philip Gold, MD. Diseases of the stress system I focus on melancholia and
differential pathophysical mechanisms in major depression and Cushing\''s disease;
diseases of the stress system II focus on a final common pathway in the atypical
depressive syndromes in Cushing\''s disease, seasonal affective disorder, chronic
fatigue syndrome and hypothyroidism; diseases of the stress system III focus on
the role of the central nervous system in the susceptibility to inflammatory disease;
common pathophysiological features in eating, obsessional, and affective disorders
using neuroanatomical, molecular neuroendocrinology, and behavioral studies; basic
and clinical implications of the influence of viral proteins on neuropeptide gene
expression.
</LI>
</UL>
<H4>Clinical Neurogenetics Branch</H4>
<UL>
<LI>Elliott Gershon, MD. In psychiatric disorders (bipolar illness, schizophrenia,
panic disorder) and human behaviors: diagnostic genetic family studies, systematic
genetic linkage mapping, and identification of disease mutations. Mathematical
modeling analysis of selected problems in linkage and association in common disease.
Direct molecular and functional examination of candidate genes based on location
within a linkage region or prior neurobiological hypotheses.
</LI>
</UL>
<H4>Clinical Neuroscience Branch</H4>
<UL>
<LI>Edward Ginns, MD, PhD. Research focuses on the genetic and biochemical mechanisms
responsible for the clinical heterogeneity in inherited neurologic and psychiatric
disorders, and the development of clinical trials based on therapies utilizing
cell transplantation, enzyme/protein replacement and gene transfer. Studies include
a) preclinical studies and clinical trials of enzyme replacement and gene transfer
in selected disorders such as Gaucher disease; b) generation of transgenic mouse
models of human inherited disorders; c) systematic mapping of the genome to find
genes involved in manic-depressive illness in the Old Order Amish; d) characterization
and mapping of trinucleotide repeat regions in the genome as candidate gene loci
for psychiatric and neurologic disorders; and e) identification of genetic loci
associated with behavioral phenotypes in inbred strains of mice.
</LI>
</UL>
<H4>Clinical Psychobiology Branch</H4>
<UL>
<LI>Thomas A. Wehr, MD. Circadian rhythms in healthy volunteers and in patients
with rapid cycling bipolar disorder; effects of sleep, wakefulness, and light
on affective illness; human photoperiodic responses.
</LI>
<LI>Norman Rosenthal, MD. Effects of light and the seasons on human mood, behavior,
biochemistry and physiology; visual input and human behavior; serotonergic dysregulation
in mood disorders.
</LI>
</UL>
<H4>Child Psychiatry Branch</H4>
<UL>
<LI>Judith Rapoport, MD. Biological aspects of child psychiatry; brain imaging
techniques (PET and MRI) and psychopharmacology are major tools for four broad
areas of research (developmental disabilities, obsessive- compulsive disorder,
schizophrenia and hyperactivity).
</LI>
</UL>
<H4>Clinical Brain Disorders Brain</H4>
<UL>
<LI>Daniel Weinberger, MD.
</LI>
<LI>Joel Kleinman, MD, PhD. Neurobiology of schizophrenia; brain imaging; neuropsychology;
neuropathology and Tourette\''s syndrome.
</LI>
</UL>
<H4>Experimental Therapeutics Branch</H4>
<UL>
<LI>David Pickar, MD. Research on serious mental illnesses (schizophrenia and
affective disorders), which includes studies of pathophysiologic mechanisms and
new treatment strategies; the program utilizes PET, MRI and other recently developed
research strategies in tandem with neuropharmacologic techniques.
</LI>
<LI>William Z. Potter, MD, PhD. Mechanisms of action of lithium and antidepressants;
pathophysiology and treatment of bipolar affective illness; neurotransmitter interactions;
adrenergic receptors; G proteins; second messengers and intracellular "cross-talk."
</LI>
</UL>
<H4>Laboratory of Clinical Science</H4>
<UL>
<LI>Dennis L. Murphy, MD. Serotonin in neuropsychiatric disorders; obsessive-compulsive
disorder; monoamine oxidase (MAO) and MAO inhibitors; memory, cholinergic function,
aging, and Alzheimer\''s disease.
</LI>
<LI>Trey Sunderland, MD. Neurobiology of Alzheimer\''s disease and geriatric depression;
psychopharmacologic modeling of memory disorders; monoamine oxidase (MAO) inhibitors;
pharmacologic treatment of Alzheimer\''s disease and other memory disorders of
aging.
</LI>
</UL>
<H4>Neuropsychiatry Branch</H4>
<UL>
<LI>Richard J. Wyatt, MD. Molecular immunologic and cellular approaches to the
study of HIV-1 and schizophrenia; neurochemical, neurophysiological and PET abnormalities
and pharmacological treatment of schizophrenia and related disorders; intracerebral
transplantation of cells and tissue and afferent regulation of the striatum.
</LI>
</UL>
<H3>Examples of Papers Authored by Program Faculty</H3>
<UL>
<LI>Post RM. Sensitization and kindling perspectives for the course of affective
illness: toward a new treatment with the anticonvulsant carbamazepine. Pharmacopsychiatry
1990;23:3-17. Schmidt PJ, Nieman LK, Grover GN, Muller KL, Merriam GM, Rubinow
DR. Lack of effect of induced menses on symptoms in women with premenstrual syndrome.
N Engl J Med 1991;324:1174-1179.
</LI>
<LI>Suddath RL, Christison GW, Torrey EF, Weinberger DR. Cerebral anatomical abnormalities
in monozygotic twins discordant for schizophrenia. N Engl J Med 1990;322:789-794.
</LI>
<LI>Gejman PV, Ram A, Gelernter J, Friedman E, Cao Q, Pickar D, Blum K, Noble
EP, Kranzler HR, O\''Malley S, Hamer DH, Whitsitt F, Rao P, Delisi LE, Virkkunen
M, Linnoila M, Goldman D, Gershon ES. No structural mutation in the dopamine D2
receptor gene in alcoholism or schizophrenia. Analysis using denaturing gradient
gel electrophoresis. J Am Med Assoc 1994;271:204-208.
</LI>
<LI>Berrettini WH, Ferraro TN, Goldin LR, Weeks DE, Detera-Wadleigh SD, Nurnberger
JI Jr, Gershon ES. Chromosome 18 DNA markers and manic- depressive illness: evidence
for a susceptibility gene. Proc Natl Acad Sci USA (in press).
</LI>
<LI>Brady LS, Whitfield HJ Jr, Fox RJ, Gold PW, Herkenham M. Long-term antidepressant
administration alters corticotropin-releasing hormone, tyrosine hypothalamic-pituitary-adrenal
hydroxylase and mineralocorticoid receptor gene expression in rat brain. Therapeutic
implications. J Clin Invest 1991;67:831-837.
</LI>
<LI>Elia J, Gulotta C, Rose SR, Gabriela M, Rapoport JL. Thyroid function and
attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1994;33:169-172.
</LI>
<LI>Rosenthal NE, Wehr TA. Towards understanding the mechanism of action of light
in seasonal affective disorder. Pharmacopsychiatry 1992;25:56- 60.
</LI>
</UL>
<H3>Program Graduates</H3>
<P>The following is a list of recent graduates including their current positions:</P>
<UL>
<LI>Dr. Robert Alexander. Assistant Professor, Thomas Jefferson University, Philadelphia,
Pennsylvania.
</LI>
<LI>Dr. Lori Altschuler. Assistant Clinical Professor at UCLA and Brentwood Veterans
Administration Hospital, Los Angeles, California.
</LI>
<LI>Dr. Wade H. Berrettini. Professor of Psychiatry, Thomas Jefferson Medical
College, Philadelphia, Pennsylvania.
</LI>
<LI>Dr. Mark Demitrack. Assistant Professor, Department of Psychiatry, University
of Michigan Medical Center, Ann Arbor, Michigan.
</LI>
<LI>Dr. Josephine Elia, Staff Child Psychiatrist at the Medical College of Pennsylvania,
Philadelphia, Pennsylvania.
</LI>
<LI>Dr. Joel Gelernter. Assistant Professor of Psychiatry, Yale School of Medicine,
New Haven, Connecticut.
</LI>
<LI>Dr. Robert Golden. Associate Professor of Psychiatry, The University of North
Carolina, Chapel Hill, North Carolina.
</LI>
<LI>Dr. George Jaskiw. Case Western Reserve University, Cleveland, Ohio.
</LI>
<LI>Dr. Rick L. Martinez. Medical Officer, Laboratory of Clinical Science, National
Institute of Mental Health, Bethesda, Maryland.
</LI>
<LI>Dr. Alan Mellow. Assistant Professor of Psychiatry, University of Michigan
Medical Center, Ann Arbor, Michigan.
</LI>
<LI>Dr. Dan A. Oren. Clinical Psychobiology Branch, National Institute of Mental
Health, Bethesda, Maryland.
</LI>
<LI>Dr. Richard Owen. Staff Physician, Veterans Administration, Assistant Professor,
University of Arkansas, Little Rock, Arkansas.
</LI>
<LI>Dr. Barbara Parry. Associate Professor of Psychiatry, University of California,
San Diego, California.
</LI>
<LI>Dr. Emile Risby. Assistant Professor, Department of Psychiatry, Emory University,
Atlanta, Georgia.
</LI>
<LI>Dr. Murray Stein. Assistant Professor of Psychiatry, Department of Psychiatry,
University of Manitoba, Winnipeg, Manitoba, Canada.
</LI>
<LI>Dr. Manuel Tancer. Assistant Professor of Psychiatry, Department of Psychiatry,
University of North Carolina, Chapel Hill, North Carolina.
</LI>
<LI>Dr. M-L Wong. Neuropsychiatric Unit, Veterans Administration Medical Center,
Yale University, West Haven, Connecticut.
</LI>
</UL>
<H3>Application Information</H3>
<P>The NIMH Intramural Research Program offers an Accreditation Council for Graduate
Medical Education/ACNP approved psychiatric residency program for PGY-4 and above
only. Eligible residents sit for the American Board of Psychiatry and Neurology.</P>
<P>Applicants must successfully complete three years (including all clinical requirements
for certification) in an approved Accreditation Council for Graduate Medical Education
general psychiatry residency prior to matriculation. All pathways available are
considered.</P>
<P>The number of positions varies between six to thirteen per year. Interested
applicants are encouraged to apply during their PGY-2 or PGY- 3 year of training.
The expected length of stay for associates participating in the program is two
years, with limited opportunities for additional training years.</P>
<P>For further information, the applicant should contact:</P>
<BLOCKQUOTE>
Barry B. Kaplan, PhD<BR>
Associate Director for Fellowship Training<BR>
Division of Intramural Research Programs<BR>
National Institute of Mental Health<BR>
National Institutes of Health<BR>
Building 10, Room 4N272<BR>
10 CENTER DR MSC 1381<BR>
BETHESDA MD 20892-1381<BR>
301-496-3501<BR>
FAX: 301-402-2588
</BLOCKQUOTE>
<H3>Electronic Application</H3>
<P>The quickest and easiest way to find out more about this training program or
to apply for consideration is to do it electronically. Press the appropriate button
below to request further information or apply for consideration.</P>